Patients with this genetic polymorphism are potentially at higher risk of the decreased therapeutic effect of diazepam?
Skryabin VY et al. recently evaluated the effects of CYP2C19 genetic polymorphisms on the steady state concentration of diazepam in patients with alcohol withdrawal syndrome. They postulate that those patients who carry the *1/*1 and *17/*17 genotypes have a higher risk of decreased therapeutic effect of diazepam.
Skryabin VY et al. Effects of CYP2C19*17 Genetic Polymorphisms on the Steady State Concentration of Diazepam in Patients with Alcohol Withdrawal Syndrome. Hospital Pharmacy 2021; 56(5): 592-596. doi/10.1177/0018578720931756